{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "import json\n",
    "import pandas as pd\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "data = [\n",
    "                    {\n",
    "                        \"measure\": \"Number of Participants Achieving Complete Response (Using Disease Activity Score Based on 28-joint Count, Modified Total Sharp Score, Health Assessment Questionnaire)\",\n",
    "                        \"description\": \"<p>The composite measure of complete response over the last 3 months of Phase 1 was defined as:</p><ol><li>DAS28 &lt;2.6 at the week 39 and 52 visits and,</li><li>No radiographic progression during Phase 1, defined as mean change in modified total Sharp score (mTSS) ≤0.5 and,</li><li>Health Assessment Questionnaire (HAQ) ≤ 0.5 at the week 39 and week 52 visits</li></ol>\",\n",
    "                        \"timeFrame\": \"End of Phase 1\"\n",
    "                    },\n",
    "                    {\n",
    "                        \"measure\": \"Change From Baseline in Modified Total Sharp Score (mTSS) at Week 52 and Final on Therapy\",\n",
    "                        \"description\": \"mTSS = sum of erosion and Joint Space Narrowing (JSN) scores for 44 joints (16 per hand and 6 per foot).\\nmTSS scores ranged from 0 (normal) to 448 (worst possible total score).\\nChange: scores at observation minus score at baseline.\\nAn increase in mTSS from baseline.\\nAn increase in mTSS from baseline represented disease progression and&#x2F;or joint worsening, no change represented halting of disease progression, and a decrease represented improvement.\",\n",
    "                        \"timeFrame\": \"52 week and Final on Therapy (includes all visits for a participant up to Week 52 or the visit they discontinued at)\"\n",
    "                    },\n",
    "                    {\n",
    "                        \"measure\": \"Change From Baseline in Work Productivity and Activity Impairment (WPAI) Questionnaire: Percent Overall Work Impairment Due to Problem\",\n",
    "                        \"description\": \"WPAI:6 question participant rated questionnaire to determine the degree to which rheumatoid arthritis affected work productivity while at work and affected activities outside of work.\\nFour scores are derived:percentage of absenteeism, percentage of presenteeism (reduced productivity while at work),overall work impairment score that combined absenteeism and presenteeism and percentage of impairment in activities performed outside of work.\\nScores scaled as 0 (not affected&#x2F;no impairment) to 10 (completely affected&#x2F;impaired).\\nHigher scores indicated greater impairment and less productivity.\\nThe raw scores (0-10) are converted to percents (the variable is named &quot;Percent impairment While Working&quot;) and as such range from 0 to 100.\",\n",
    "                        \"timeFrame\": \"13, 26, 39, 52 weeks and Final on Therapy (includes all visits for a participant up to Week 52 or the visit they discontinued at)\"\n",
    "                    },\n",
    "                    {\n",
    "                        \"measure\": \"Change From Baseline in Work Productivity and Activity Impairment (WPAI) Questionnaire: Percent Impairment While Working Due to Problem\",\n",
    "                        \"description\": \"WPAI:6 question participant rated questionnaire to determine the degree to which rheumatoid arthritis affected work productivity while at work and affected activities outside of work.\\nFour scores are derived:percentage of absenteeism, percentage of presenteeism (reduced productivity while at work),overall work impairment score that combined absenteeism and presenteeism and percentage of impairment in activities performed outside of work.\\nScores scaled as 0 (not affected&#x2F;no impairment) to 10 (completely affected&#x2F;impaired).\\nHigher scores indicated greater impairment and less productivity.\\nThe raw scores (0-10) are converted to percents (the variable is named &quot;Percent impairment While Working&quot;) and as such range from 0 to 100.\",\n",
    "                        \"timeFrame\": \"13, 26, 39, 52 weeks and Final on Therapy (includes all visits for a participant up to Week 52 or the visit they discontinued at)\"\n",
    "                    },\n",
    "                    {\n",
    "                        \"measure\": \"Change From Baseline in Work Productivity and Activity Impairment (WPAI) Questionnaire: Percent Work Time Missed Due to Problem\",\n",
    "                        \"description\": \"WPAI:6 question participant rated questionnaire to determine the degree to which rheumatoid arthritis affected work productivity while at work and affected activities outside of work.\\nFour scores are derived:percentage of absenteeism, percentage of presenteeism (reduced productivity while at work),overall work impairment score that combined absenteeism and presenteeism and percentage of impairment in activities performed outside of work.\\nScores scaled as 0 (not affected&#x2F;no impairment) to 10 (completely affected&#x2F;impaired).\\nHigher scores indicated greater impairment and less productivity.\\nThe raw scores (0-10) are converted to percents (the variable is named &quot;Percent impairment While Working&quot;) and as such range from 0 to 100.\",\n",
    "                        \"timeFrame\": \"13, 26, 39, 52 weeks and Final on Therapy (includes all visits for a participant up to Week 52 or the visit they discontinued at)\"\n",
    "                    },\n",
    "                    {\n",
    "                        \"measure\": \"Change From Baseline in Work Productivity and Activity Impairment (WPAI) Questionnaire: Percent Activity Impairment Due to Problem\",\n",
    "                        \"description\": \"WPAI:6 question participant rated questionnaire to determine the degree to which rheumatoid arthritis affected work productivity while at work and affected activities outside of work.\\nFour scores are derived:percentage of absenteeism, percentage of presenteeism (reduced productivity while at work),overall work impairment score that combined absenteeism and presenteeism and percentage of impairment in activities performed outside of work.\\nScores scaled as 0 (not affected&#x2F;no impairment) to 10 (completely affected&#x2F;impaired).\\nHigher scores indicated greater impairment and less productivity.\\nThe raw scores (0-10) are converted to percents (the variable is named &quot;Percent impairment While Working&quot;) and as such range from 0 to 100.\",\n",
    "                        \"timeFrame\": \"13, 26, 39, 52 weeks and Final on Therapy (includes all visits for a participant up to Week 52 or the visit they discontinued at)\"\n",
    "                    },\n",
    "                    {\n",
    "                        \"measure\": \"Number of Participants Achieving American College of Rhematology 20% (ACR 20) Response\",\n",
    "                        \"description\": \"ACR20 response: greater than or equal to (≥) 20 percent (%) improvement in tender joint count; ≥ 20% improvement in swollen joint count; and ≥ 20% improvement in at least 3 of 5 remaining ACR core measures: 1) physician&#x27;s global assessment of disease activity, 2) subject&#x27;s assessment of disease activity, 3) subject&#x27;s assessment of pain, 4) subject&#x27;s assessment of functional disability via a health assessment questionnaire, and 5) C-reactive protein at each visit.\",\n",
    "                        \"timeFrame\": \"2, 4, 8, 13, 26, 39, 52 weeks and Final on Therapy (includes all visits for a participant up to Week 52 or the visit they discontinued at)\"\n",
    "                    },\n",
    "                    {\n",
    "                        \"measure\": \"Number of Participants Achieving American College of Rhematology 50% (ACR 50) Response\",\n",
    "                        \"description\": \"ACR50 response: greater than or equal to (≥) 50 percent (%) improvement in tender or swollen joint counts and 50% improvement in 3 of the following 5 criteria: 1) physician&#x27;s global assessment of disease activity, 2) subject&#x27;s assessment of disease activity, 3) subject&#x27;s assessment of pain, 4) subject&#x27;s assessment of functional disability via a health assessment questionnaire, and 5) C-reactive protein at each visit.\",\n",
    "                        \"timeFrame\": \"2, 4, 8, 13, 26, 39, 52 weeks and Final on Therapy (includes all visits for a participant up to Week 52 or the visit they discontinued at)\"\n",
    "                    },\n",
    "                    {\n",
    "                        \"measure\": \"Number of Participants Achieving American College of Rhematology 70% (ACR 70) Response\",\n",
    "                        \"description\": \"ACR70 response: greater than or equal to (≥) 70 percent (%) improvement in tender or swollen joint counts and 70% improvement in 3 of the following 5 criteria: 1) physician&#x27;s global assessment of disease activity, 2) subject&#x27;s assessment of disease activity, 3) subject&#x27;s assessment of pain, 4) subject&#x27;s assessment of functional disability via a health assessment questionnaire, and 5) C-reactive protein at each visit.\",\n",
    "                        \"timeFrame\": \"2, 4, 8, 13, 26, 39, 52 weeks and Final on Therapy (includes all visits for a participant up to Week 52 or the visit they discontinued at)\"\n",
    "                    },\n",
    "                    {\n",
    "                        \"measure\": \"Number of Participants Achieving American College of Rhematology 90% (ACR 90) Response\",\n",
    "                        \"description\": \"ACR90 response: greater than or equal to (≥) 90 percent (%) improvement in tender or swollen joint counts and 90% improvement in 3 of the following 5 criteria: 1) physician&#x27;s global assessment of disease activity, 2) subject&#x27;s assessment of disease activity, 3) subject&#x27;s assessment of pain, 4) subject&#x27;s assessment of functional disability via a health assessment questionnaire, and 5) C-reactive protein at each visit.\",\n",
    "                        \"timeFrame\": \"2, 4, 8, 13, 26, 39, 52 weeks and Final on Therapy (includes all visits for a participant up to Week 52 or the visit they discontinued at)\"\n",
    "                    },\n",
    "                    {\n",
    "                        \"measure\": \"Change From Baseline in Physician&#x27;s Global Assessment of Disease Activity\",\n",
    "                        \"description\": \"Physician Global Assessment of Disease Activity was measured on a 0 to 100 Visual Analog Scale (VAS), with 0 = no disease activity and 100 = extreme disease activity.\",\n",
    "                        \"timeFrame\": \"2, 4, 8, 13, 26, 39, 52 weeks and Final on Therapy (includes all visits for a participant up to Week 52 or the visit they discontinued at)\"\n",
    "                    },\n",
    "                    {\n",
    "                        \"measure\": \"Change From Baseline in Participant&#x27;s Global Assessment of Disease Activity\",\n",
    "                        \"description\": \"Participant&#x27;s Global Assessment of Disease Activity was measured on a 0 to 100 mm Visual Analog Scale (VAS), with 0 mm = no disease activity and 100 = extreme disease activity\",\n",
    "                        \"timeFrame\": \"2, 4, 8, 13, 26, 39, 52 weeks and Final on Therapy (includes all visits for a participant up to Week 52 or the visit they discontinued at)\"\n",
    "                    },\n",
    "                    {\n",
    "                        \"measure\": \"Change From Baseline in DAS44 Score at All Visits\",\n",
    "                        \"description\": \"DAS44 calculated from the number of swollen joints (SJC) and painful joints (PJC) using the 44 joints count, the erythrocyte sedimentation rate (ESR) (millimeters per hour [mm&#x2F;hour]) and patient&#x27;s global assessment (PGA) of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity).\\nDAS44 &lt;1.6 = clinical remission, DAS44 ≤2.4 = low disease activity.\",\n",
    "                        \"timeFrame\": \"2, 4, 8, 13, 26, 39, 52 weeks and Final on Therapy (includes all visits for a participant up to Week 52 or the visit they discontinued at)\"\n",
    "                    },\n",
    "                    {\n",
    "                        \"measure\": \"Number of Participants With Disease Activity Score Based on 44-joints Count (DAS44)-Remission\",\n",
    "                        \"description\": \"DAS44 calculated from the number of swollen joints (SJC) and painful joints (PJC) using the 44 joints count, the erythrocyte sedimentation rate (ESR) (millimeters per hour [mm&#x2F;hour]) and patient&#x27;s global assessment (PGA) of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity).\\nDAS44 &lt;1.6 = clinical remission, DAS44 ≤2.4 = low disease activity.\",\n",
    "                        \"timeFrame\": \"2, 4, 8, 13, 26, 39, 52 weeks and Final on Therapy (includes all visits for a participant up to Week 52 or the visit they discontinued at)\"\n",
    "                    },\n",
    "                    {\n",
    "                        \"measure\": \"Number of Participants With Disease Activity Score Based on 44-joints Count (DAS44) - Low Disease Activity\",\n",
    "                        \"description\": \"DAS44 calculated from the number of swollen joints (SJC) and painful joints (PJC) using the 44 joints count, the erythrocyte sedimentation rate (ESR) (millimeters per hour [mm&#x2F;hour]) and patient&#x27;s global assessment (PGA) of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity).\\nDAS44 &lt;1.6 = clinical remission, DAS44 ≤2.4 = low disease activity.\",\n",
    "                        \"timeFrame\": \"2, 4, 8, 13, 26, 39, 52 weeks and Final on Therapy (includes all visits for a participant up to Week 52 or the visit they discontinued at)\"\n",
    "                    },\n",
    "                    {\n",
    "                        \"measure\": \"Proportion of Subjects Achieving a Patient Acceptable Symptom State (PASS) at Each Visit\",\n",
    "                        \"description\": \"The PASS is defined as a symptom state that the participants consider acceptable.\",\n",
    "                        \"timeFrame\": \"2, 4, 8, 13, 26, 39, 52 weeks and Final on Therapy (includes all visits for a participant up to Week 52 or the visit they discontinued at)\"\n",
    "                    },\n",
    "                    {\n",
    "                        \"measure\": \"Number of Participants With an American College of Rheumatology 20% (ACR20) Response\",\n",
    "                        \"description\": \"ACR20 response: greater than or equal to (≥) 20 percent (%) improvement in tender joint count; ≥ 20% improvement in swollen joint count; and ≥ 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP).\",\n",
    "                        \"timeFrame\": \"52, 56, 64, 76, 91 weeks and Final on Therapy (includes all visits for a participant up to Week 91 or the visit they discontinued at)\"\n",
    "                    },\n",
    "                    {\n",
    "                        \"measure\": \"Number of Participants Achieving American College of Rheumatology 50% (ACR50) Response\",\n",
    "                        \"description\": \"ACR50 response: greater than or equal to (≥) 50 percent (%) improvement in tender or swollen joint counts and 50% improvement in 3 of the following 5 criteria: 1) physician&#x27;s global assessment of disease activity, 2) subject&#x27;s assessment of disease activity, 3) subject&#x27;s assessment of pain, 4) subject&#x27;s assessment of functional disability via a health assessment questionnaire, and 5) C-reactive protein at each visit.\",\n",
    "                        \"timeFrame\": \"52, 56, 64, 76, 91 weeks and Final on Therapy (includes all visits for a participant up to Week 91 or the visit they discontinued at)\"\n",
    "                    },\n",
    "                    {\n",
    "                        \"measure\": \"Number of Participants Achieving American College of Rheumatology 70% (ACR70) Response\",\n",
    "                        \"description\": \"ACR70 response: greater than or equal to (≥) 70 percent (%) improvement in tender or swollen joint counts and 70% improvement in 3 of the following 5 criteria: 1) physician&#x27;s global assessment of disease activity, 2) subject&#x27;s assessment of disease activity, 3) subject&#x27;s assessment of pain, 4) subject&#x27;s assessment of functional disability via a health assessment questionnaire, and 5) C-reactive protein at each visit.\",\n",
    "                        \"timeFrame\": \"52, 56, 64, 76, 91 weeks and Final on Therapy (includes all visits for a participant up to Week 91 or the visit they discontinued at)\"\n",
    "                    },\n",
    "                    {\n",
    "                        \"measure\": \"Number of Participants Achieving American College of Rheumatology 90% (ACR90) Response\",\n",
    "                        \"description\": \"ACR90 response: greater than or equal to (≥) 90 percent (%) improvement in tender or swollen joint counts and 90% improvement in 3 of the following 5 criteria: 1) physician&#x27;s global assessment of disease activity, 2) subject&#x27;s assessment of disease activity, 3) subject&#x27;s assessment of pain, 4) subject&#x27;s assessment of functional disability via a health assessment questionnaire, and 5) C-reactive protein at each visit.\",\n",
    "                        \"timeFrame\": \"52, 64, 76, 91 weeks and Final on Therapy (includes all visits for a participant up to Week 91 or the visit they discontinued at)\"\n",
    "                    },\n",
    "                    {\n",
    "                        \"measure\": \"Number of Participants With Disease Activity Score Based on 44-joints Count (DAS44) Remission\",\n",
    "                        \"description\": \"DAS44 calculated from the number of swollen joints (SJC) and painful joints (PJC) using the 44 joints count, the erythrocyte sedimentation rate (ESR) (millimeters per hour [mm&#x2F;hour]) and patient&#x27;s global assessment (PGA) of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity).\\nDAS44 &lt;1.6 = clinical remission, DAS44 ≤2.4 = low disease activity.\",\n",
    "                        \"timeFrame\": \"52, 56, 64, 76, 91 weeks and Final on Therapy (includes all visits for a participant up to Week 91 or the visit they discontinued at)\"\n",
    "                    },\n",
    "                    {\n",
    "                        \"measure\": \"Number of Participants With Disease Activity Score Based on 44-joints Count (DAS44) - Low Disease Activity\",\n",
    "                        \"description\": \"DAS44 calculated from the number of swollen joints (SJC) and painful joints (PJC) using the 44 joints count, the erythrocyte sedimentation rate (ESR) (millimeters per hour [mm&#x2F;hour]) and patient&#x27;s global assessment (PGA) of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity).\\nDAS44 &lt;1.6 = clinical remission, DAS44 ≤2.4 = low disease activity.\",\n",
    "                        \"timeFrame\": \"52, 56, 64, 76, 91 weeks and Final on Therapy (includes all visits for a participant up to Week 91 or the visit they discontinued at)\"\n",
    "                    },\n",
    "                    {\n",
    "                        \"measure\": \"Number of Participants Achieving Complete Response (Using Disease Activity Score Based on a 28-joint Count, Modified Total Sharp Score, Health Assessment Questionnaire)\",\n",
    "                        \"description\": \"<p>The composite measure of complete response over the last 3 months of Phase 2 was defined as:</p><ol><li>DAS28 &lt;2.6 at the Week 76 and Week 91 visits and</li><li>No radiographic progression during Phase 2, defined as mean change from Week 52 in mTSS of ≤0.5.</li><li>Participant must achieve HAQ score ≤0.5 at Week 76 and 91 visits.\\nHAQ is self-reported, valid assessment of functional disability in rheumatoid arthritis.\\nAssessed based on ability of participants to perform daily activities in 8 categories: dressing, arising, eating, walking, reaching, gripping, hygiene, and carrying out daily activities.\\nHAQ score range: 0-3: without any difficulty=0, with some difficulty=1, with much difficulty=2, unable to do=3.\\nHAQ total scores expressed as overall mean score with range 0-3: 0-0.25=normal functioning; 0.25-0.5=mild\\nfunctional limitation; 0.5-1=moderate functional limitation; more than 1=significant functional limitation.A subject had to satisfy all 3 criteria at thevisits to be defined as a responder</li></ol>\",\n",
    "                        \"timeFrame\": \"52 and 91 weeks\"\n",
    "                    },\n",
    "                    {\n",
    "                        \"measure\": \"Physician&#x27;s Global Assessment of Disease Activity\",\n",
    "                        \"description\": \"Physician Global Assessment of Disease Activity was measured on a 0 to 100 Visual Analog Scale (VAS), with 0 = no disease activity and 100 = extreme disease activity.\",\n",
    "                        \"timeFrame\": \"52, 56, 64, 76, 91 weeks and Final on Therapy (includes all visits for a participant up to Week 91 or the visit they discontinued at)\"\n",
    "                    },\n",
    "                    {\n",
    "                        \"measure\": \"Participant&#x27;s Global Assessment of Disease Activity\",\n",
    "                        \"description\": \"Participant&#x27;s Global Assessment of Disease Activity was measured on a 0 to 100 mm Visual Analog Scale (VAS), with 0 mm = no disease activity and 100 = extreme disease activity\",\n",
    "                        \"timeFrame\": \"52, 56, 64, 76, 91 weeks and Final on Therapy (includes all visits for a participant up to Week 91 or the visit they discontinued at)\"\n",
    "                    },\n",
    "                    {\n",
    "                        \"measure\": \"Participant&#x27;s Global Assessment of Pain (Visual Analogue Scale) (VAS)\",\n",
    "                        \"description\": \"100-mm line (Visual Analog Scale) marked by the participant to measure their degree of pain over past 2-3 weeks.\\nRange: 0 = no pain to 100 = pain as bad as it could be.\",\n",
    "                        \"timeFrame\": \"52, 56, 64, 76, 91 weeks and Final on Therapy (includes all visits for a participant up to Week 91 or the visit they discontinued at)\"\n",
    "                    },\n",
    "                    {\n",
    "                        \"measure\": \"Number of Participants Achieving Patient Acceptable Symptom State (PASS)\",\n",
    "                        \"description\": \"The PASS is defined as a symptom state that the subjects consider acceptable.\",\n",
    "                        \"timeFrame\": \"52, 56, 64, 76, 91 weeks and Final on Therapy (includes all visits for a participant up to Week 91 or the visit they discontinued at)\"\n",
    "                    },\n",
    "                    {\n",
    "                        \"measure\": \"Modified Total Sharp Score (mTSS) at Week 52\",\n",
    "                        \"description\": \"mTSS = sum of erosion and Joint Space Narrowing (JSN) scores for 44 joints (16 per hand and 6 per foot).\\nmTSS scores ranged from 0 (normal) to 448 (worst possible total score).\\nChange: scores at observation minus score at baseline.\\nAn increase in mTSS from baseline represented disease progression and&#x2F;or joint worsening, no change represented halting of disease progression, and a decrease represented improvement.\",\n",
    "                        \"timeFrame\": \"52 weeks\"\n",
    "                    },\n",
    "                    {\n",
    "                        \"measure\": \"Change From Baseline mTSS at Week 91 and Final on Therapy\",\n",
    "                        \"description\": \"mTSS = sum of erosion and Joint Space Narrowing (JSN) scores for 44 joints (16 per hand and 6 per foot).\\nmTSS scores ranged from 0 (normal) to 448 (worst possible total score).\\nChange: scores at observation minus score at baseline.\\nAn increase in mTSS from baseline represented disease progression and&#x2F;or joint worsening, no change represented halting of disease progression, and a decrease represented improvement.\",\n",
    "                        \"timeFrame\": \"91 weeks and Final on Therapy (includes all visits for a participant up to Week 91 or the visit they discontinued at)\"\n",
    "                    },\n",
    "                    {\n",
    "                        \"measure\": \"Work Productivity and Activity Impairment (WPAI) Questionnaire: Percent Work Time Missed in the Past 7 Days Due to Problem\",\n",
    "                        \"description\": \"WPAI: 6 question participant rated questionnaire to determine the degree to which rheumatoid arthritis affected work productivity while at work and affected activities outside of work.\\nFour scores are derived: percentage of absenteeism, percentage of presenteeism (reduced productivity while at work), an overall work impairment score that combined absenteeism and presenteeism and percentage of impairment in activities performed outside of work.\\nScores scaled as 0 (not affected&#x2F;no impairment) to 10 (completely affected&#x2F;impaired).\\nHigher scores indicated greater impairment and less productivity.\\nThe raw (0-10) scores are converted to percents (the variable is named &quot;Percent impairment While Working&quot;) and as such range from 0 to 100.\",\n",
    "                        \"timeFrame\": \"52 weeks\"\n",
    "                    },\n",
    "                    {\n",
    "                        \"measure\": \"Change From Baseline in WPAI Questionnaire: Percent Work Time Missed in the Past 7 Days Due to Problem\",\n",
    "                        \"description\": \"WPAI is a 6 question participant rated questionnaire determined the degree to which rheumatoid arthritis affected work productivity while at work and affected activities outside of work.\\nScores scaled as 0 (not affected&#x2F;no impairment) to 10 (completely affected&#x2F;impaired).\\nHigher scores = greater impairment and less productivity.\\nThe raw (0-10) scores were converted to percent (the variable is named &quot;Percent impairment While Working&quot;) and as such range from 0 to 100.\",\n",
    "                        \"timeFrame\": \"64, 76, 91 weeks and Final on Therapy (includes all visits for a participant upto Week 91 or the visit they discontinued at)\"\n",
    "                    },\n",
    "                    {\n",
    "                        \"measure\": \"WPAI Questionnaire: Percent Impairment While Working in the Past 7 Days Due to Problem\",\n",
    "                        \"description\": \"WPAI: 6 question participant rated questionnaire to determine the degree to which rheumatoid arthritis affected work productivity while at work and affected activities outside of work.\\nFour scores are derived: percentage of absenteeism, percentage of presenteeism (reduced productivity while at work), an overall work impairment score that combined absenteeism and presenteeism and percentage of impairment in activities performed outside of work.\\nScores scaled as 0 (not affected&#x2F;no impairment) to 10 (completely affected&#x2F;impaired).\\nHigher scores indicated greater impairment and less productivity.\\nThe raw (0-10) scores are converted to percents (the variable is named &quot;Percent impairment While Working&quot;) and as such range from 0 to 100.\",\n",
    "                        \"timeFrame\": \"52 Weeks\"\n",
    "                    },\n",
    "                    {\n",
    "                        \"measure\": \"Change From Baseline in WPAI Questionnaire: Percent Impairment While Working in the Past 7 Days Due to Problem\",\n",
    "                        \"description\": \"WPAI: 6 question participant rated questionnaire determined the degree to which rheumatoid arthritis affected work productivity while at work and affected activities outside of work.\\nScores scaled as 0 (not affected&#x2F;no impairment) to 10 (completely affected&#x2F;impaired).\\nHigher scores = greater impairment and less productivity.\\nThe raw (0-10) scores were converted to percent (the variable is named &quot;Percent impairment While Working&quot;) and as such range from 0 to 100.\",\n",
    "                        \"timeFrame\": \"64, 76, 91 weeks and Final on Therapy (includes all visits for a participant upto Week 91 or the visit they discontinued at)\"\n",
    "                    },\n",
    "                    {\n",
    "                        \"measure\": \"WPAI Questionnaire: Percent Overall Work Impairment in the Past 7 Days Due to Problem\",\n",
    "                        \"description\": \"WPAI: 6 question participant rated questionnaire to determine the degree to which rheumatoid arthritis affected work productivity while at work and affected activities outside of work.\\nFour scores are derived: percentage of absenteeism, percentage of presenteeism (reduced productivity while at work), an overall work impairment score that combined absenteeism and presenteeism and percentage of impairment in activities performed outside of work.\\nScores scaled as 0 (not affected&#x2F;no impairment) to 10 (completely affected&#x2F;impaired).\\nHigher scores indicated greater impairment and less productivity.\\nThe raw (0-10) scores are converted to percents (the variable is named &quot;Percent impairment While Working&quot;) and as such range from 0 to 100.\",\n",
    "                        \"timeFrame\": \"52 weeks\"\n",
    "                    },\n",
    "                    {\n",
    "                        \"measure\": \"Change From Baseline in WPAI Questionnaire: Percent Overall Work Impairment in the Past 7 Days Due to Problem\",\n",
    "                        \"description\": \"WPAI: 6 question participant rated questionnaire determined the degree to which rheumatoid arthritis affected work productivity while at work and affected activities outside of work.\\nScores scaled as 0 (not affected&#x2F;no impairment) to 10 (completely affected&#x2F;impaired).\\nHigher scores = greater impairment and less productivity.\\nThe raw (0-10) scores were converted to percent (the variable is named &quot;Percent impairment While Working&quot;) and as such range from 0 to 100.\",\n",
    "                        \"timeFrame\": \"64, 76, 91 weeks and Final on Therapy (includes all visits for a participant upto Week 91 or the visit they discontinued at)\"\n",
    "                    },\n",
    "                    {\n",
    "                        \"measure\": \"WPAI Questionnaire: Percent Activity Impairment in the Past 7 Days Due to Problem\",\n",
    "                        \"description\": \"WPAI: 6 question participant rated questionnaire to determine the degree to which rheumatoid arthritis affected work productivity while at work and affected activities outside of work.\\nFour scores are derived: percentage of absenteeism, percentage of presenteeism (reduced productivity while at work), an overall work impairment score that combined absenteeism and presenteeism and percentage of impairment in activities performed outside of work.\\nScores scaled as 0 (not affected&#x2F;no impairment) to 10 (completely affected&#x2F;impaired).\\nHigher scores indicated greater impairment and less productivity.\\nThe raw (0-10) scores are converted to percents (the variable is named &quot;Percent impairment While Working&quot;) and as such range from 0 to 100.\",\n",
    "                        \"timeFrame\": \"52 weeks\"\n",
    "                    },\n",
    "                    {\n",
    "                        \"measure\": \"Change From Baseline in WPAI Questionnaire: Percent Activity Impairment in the Past 7 Days Due to Problem\",\n",
    "                        \"description\": \"WPAI: 6 question participant rated questionnaire determined the degree to which rheumatoid arthritis affected work productivity while at work and affected activities outside of work.\\nScores scaled as 0 (not affected&#x2F;no impairment) to 10 (completely affected&#x2F;impaired).\\nHigher scores = greater impairment and less productivity.\\nThe raw (0-10) scores were converted to percent (the variable is named &quot;Percent impairment While Working&quot;) and as such range from 0 to 100.\",\n",
    "                        \"timeFrame\": \"64, 76, 91 weeks and Final on Therapy (includes all visits for a participant upto Week 91 or the visit they discontinued at)\"\n",
    "                    }\n",
    "                ]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [],
   "source": [
    "pd.DataFrame(data).to_excel(\"ethotrexate_in_Early_Rheumatoid_Arthritis.xlsx\") "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Study Evaluating Etanercept Plus Methotrexate in Early Rheumatoid Arthritis\n",
    "# https://clinicaltrials.gov/study/NCT00913458?cond=Rheumatoid%20Arthritis&aggFilters=phase:4%203,status:com&rank=1"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Role of Nitazoxanide and Escitalopram in Patients With Rheumatoid Arthritis\n",
    "# https://clinicaltrials.gov/study/NCT05480878?cond=Rheumatoid%20Arthritis&aggFilters=phase:4%203,status:com&rank=6"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Anti-Inflammatory Diet Effect in Rheumatoid Arthritis Patients (AIDE-RAP)\n",
    "# https://clinicaltrials.gov/study/NCT05254223?cond=Rheumatoid%20Arthritis&aggFilters=phase:4%203%200%201%202%20NA,status:com&rank=8"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [],
   "source": [
    "# A Phase 2 Study of Hemay007 in Patients With Rheumatoid Arthritis\n",
    "# https://clinicaltrials.gov/study/NCT05247216?cond=Rheumatoid%20Arthritis&aggFilters=phase:4%203%200%201%202%20NA,status:com&rank=13"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Montelukast Use in Rheumatoid Arthritis\n",
    "# https://clinicaltrials.gov/study/NCT05447520?cond=Rheumatoid%20Arthritis&aggFilters=phase:4%203%200%201%202%20NA,status:com&rank=17"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Evaluating the Effect of Digoxin and Ursodeoxycholic Acid in Patients With Rheumatoid Arthritis\n",
    "# https://clinicaltrials.gov/study/NCT04834557?cond=Rheumatoid%20Arthritis&aggFilters=phase:4%203%200%201%202%20NA,status:com&rank=29"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "# A Study to Assess the Pharmacokinetics of Certolizumab Pegol in Adults With Active Rheumatoid Arthritis\n",
    "# https://clinicaltrials.gov/study/NCT04740814?cond=Rheumatoid%20Arthritis&aggFilters=phase:4%203%200%201%202%20NA,status:com&rank=41&tab=table"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "*\n"
     ]
    }
   ],
   "source": [
    "import numpy as np\n",
    "import plotly.graph_objects as go\n",
    "import os\n",
    "\n",
    "# Ensure the directory to store images exists\n",
    "output_dir = \"pendulum_frames_\"\n",
    "os.makedirs(output_dir, exist_ok=True)\n",
    "\n",
    "# Constants\n",
    "g = 9.81\n",
    "L = 2\n",
    "mu = 0.1\n",
    "theta_0 = np.pi / 3\n",
    "theta_dot_0 = 0\n",
    "\n",
    "def get_theta_double_dot(theta, theta_dot):\n",
    "    return -mu * theta_dot - (g / L) * np.sin(theta)\n",
    "\n",
    "def simulate_pendulum_motion(t_max, delta_t):\n",
    "    theta = theta_0\n",
    "    theta_dot = theta_dot_0\n",
    "    theta_values = []\n",
    "    theta_dot_values = []\n",
    "    \n",
    "    for time in np.arange(0, t_max, delta_t):\n",
    "        theta_values.append(theta)\n",
    "        theta_dot_values.append(theta_dot)\n",
    "        \n",
    "        theta_double_dot = get_theta_double_dot(theta, theta_dot)\n",
    "        theta += theta_dot * delta_t\n",
    "        theta_dot += theta_double_dot * delta_t\n",
    "\n",
    "    return np.array(theta_values), np.array(theta_dot_values)\n",
    "\n",
    "# Parameters\n",
    "t_max = 10\n",
    "delta_t_values = np.arange(0.1, 0.001, -0.001)\n",
    "\n",
    "# Create frames and save each as an image\n",
    "frame_count = 0\n",
    "for delta_t in delta_t_values:\n",
    "    theta_values, theta_dot_values = simulate_pendulum_motion(t_max, delta_t)\n",
    "    \n",
    "    fig = go.Figure(\n",
    "        data=[go.Scatter(x=theta_values, y=theta_dot_values, mode='lines', line=dict(color='darkorange'))],\n",
    "        layout=go.Layout(\n",
    "            title=f\"Pendulum - Time Step (delta_t): {delta_t:.4f}\",\n",
    "            xaxis_title=\"Angle θ (radians)\",\n",
    "            yaxis_title=\"Angular Velocity θ̇ (radians/s)\",\n",
    "            width=700,\n",
    "            height=700,\n",
    "            xaxis=dict(scaleanchor=\"y\"),\n",
    "            yaxis=dict(constrain='domain')\n",
    "        )\n",
    "    )\n",
    "\n",
    "    # Save each frame as a PNG\n",
    "    frame_file = os.path.join(output_dir, f\"frame_{frame_count:04d}.png\")\n",
    "    print(\"*\")\n",
    "    fig.write_image(frame_file)\n",
    "    frame_count += 1\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Frames saved successfully.\n"
     ]
    }
   ],
   "source": [
    "import numpy as np\n",
    "import matplotlib.pyplot as plt\n",
    "import os\n",
    "\n",
    "# Constants\n",
    "g = 9.81  # gravitational acceleration (m/s^2)\n",
    "L = 2     # length of pendulum (m)\n",
    "mu = 0.1  # damping coefficient\n",
    "\n",
    "# Initial conditions\n",
    "theta_0 = np.pi / 3  # initial angle (60 degrees)\n",
    "theta_dot_0 = 0      # initial angular velocity\n",
    "\n",
    "# Function to calculate angular acceleration\n",
    "def get_theta_double_dot(theta, theta_dot):\n",
    "    return -mu * theta_dot - (g / L) * np.sin(theta)\n",
    "\n",
    "# Function to simulate the pendulum motion and record θ and θ̇\n",
    "def simulate_pendulum_motion(t_max, delta_t):\n",
    "    theta = theta_0\n",
    "    theta_dot = theta_dot_0\n",
    "    theta_values = []\n",
    "    theta_dot_values = []\n",
    "    \n",
    "    for time in np.arange(0, t_max, delta_t):\n",
    "        theta_values.append(theta)\n",
    "        theta_dot_values.append(theta_dot)\n",
    "        \n",
    "        theta_double_dot = get_theta_double_dot(theta, theta_dot)\n",
    "        theta += theta_dot * delta_t\n",
    "        theta_dot += theta_double_dot * delta_t\n",
    "\n",
    "    return np.array(theta_values), np.array(theta_dot_values)\n",
    "\n",
    "# Directory for output frames\n",
    "output_dir = \"pendulum_frames_centered\"\n",
    "os.makedirs(output_dir, exist_ok=True)\n",
    "\n",
    "# Simulation parameters\n",
    "t_max = 30\n",
    "delta_t_values = np.arange(1.0, 0.001, -0.001)  # Decremental range\n",
    "\n",
    "# Comments at different stages of the simulation\n",
    "comments = [\n",
    "    \"Initial oscillations are broad, indicating high energy.\",\n",
    "    \"Damping effects gradually reduce oscillation amplitude.\",\n",
    "    \"As time progresses, pendulum motion stabilizes and slows.\",\n",
    "    \"Approaching the end: the pendulum reaches near-equilibrium, with minimal motion.\"\n",
    "]\n",
    "\n",
    "# Generate and save each frame with dynamically centered plot\n",
    "for i, delta_t in enumerate(delta_t_values):\n",
    "    theta_values, theta_dot_values = simulate_pendulum_motion(t_max, delta_t)\n",
    "    \n",
    "    # Calculate dynamic axis limits based on data range with some padding\n",
    "    x_limit = max(abs(theta_values)) * 1.1\n",
    "    y_limit = max(abs(theta_dot_values)) * 1.1\n",
    "    \n",
    "    # Plot with a large figure size\n",
    "    plt.figure(figsize=(24, 24), dpi=80)  # Large figure size for detailed plot\n",
    "    plt.plot(theta_values, theta_dot_values, color='darkorange', linewidth=5)\n",
    "    \n",
    "    # Set plot title, axis labels, and limits\n",
    "    plt.title(f\"Damped Pendulum Simulation - Phase Space Trajectory\\nCreated by Mayank Dwivedi(Data Scientist)\", fontsize=22, pad=20)\n",
    "    plt.suptitle(f\"Simulating a damped pendulum's angular displacement and velocity over time using Simple ODE modeling.\\n delta_time : {delta_t} secs\", fontsize=20, y=0.95)\n",
    "    plt.xlabel(\"Angle θ (radians)\", fontsize=18)\n",
    "    plt.ylabel(\"Angular Velocity θ̇ (radians/s)\", fontsize=18)\n",
    "    \n",
    "    # Set dynamic axis limits to fit the plot at the center of the figure\n",
    "    plt.xlim(-x_limit, x_limit)\n",
    "    plt.ylim(-y_limit, y_limit)\n",
    "    \n",
    "    # Determine which comment to display based on frame position\n",
    "    comment_index = min(i // (len(delta_t_values) // len(comments)), len(comments) - 1)\n",
    "    plt.figtext(0.5, 0.02, comments[comment_index], wrap=True, horizontalalignment='center', fontsize=20, color='green')\n",
    "    \n",
    "    # Save the frame as an image\n",
    "    frame_file = os.path.join(output_dir, f\"frame_{i:04d}.png\")\n",
    "    plt.savefig(frame_file, dpi=80)\n",
    "    plt.close()  # Close plot to save memory\n",
    "    import gc\n",
    "    print(gc.collect(), end=\"\\r\")\n",
    "print(\"Frames saved successfully.\")\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Video saved as pendulum_simulation_based_on_time.mp4\n"
     ]
    }
   ],
   "source": [
    "import imageio.v2 as imageio  # Explicitly use imageio.v2\n",
    "import os\n",
    "\n",
    "# Directory containing the image frames\n",
    "output_dir = \"pendulum_frames_centered\"\n",
    "output_video = \"pendulum_simulation_based_on_time.mp4\"\n",
    "\n",
    "# Get all the frames sorted by name\n",
    "frames = sorted([os.path.join(output_dir, f) for f in os.listdir(output_dir) if f.endswith(\".png\")])\n",
    "\n",
    "# Set up the video writer using imageio with ffmpeg\n",
    "with imageio.get_writer(output_video, fps=24, codec='libx264') as writer:\n",
    "    for frame in frames:\n",
    "        image = imageio.imread(frame)\n",
    "        writer.append_data(image)\n",
    "\n",
    "print(f\"Video saved as {output_video}\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [],
   "source": [
    "# !pip install imageio-ffmpeg --upgrade\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Frames saved successfully.\n"
     ]
    }
   ],
   "source": [
    "import numpy as np\n",
    "import matplotlib.pyplot as plt\n",
    "import os\n",
    "\n",
    "# Constants\n",
    "g = 9.81  # gravitational acceleration (m/s^2)\n",
    "L = 2     # length of pendulum (m)\n",
    "mu = 0.1  # damping coefficient\n",
    "\n",
    "# Initial conditions\n",
    "theta_0 = np.pi / 3  # initial angle (60 degrees)\n",
    "theta_dot_0 = 0      # initial angular velocity\n",
    "\n",
    "# Function to calculate angular acceleration\n",
    "def get_theta_double_dot(theta, theta_dot):\n",
    "    return -mu * theta_dot - (g / L) * np.sin(theta)\n",
    "\n",
    "# Function to simulate the pendulum motion and record θ and θ̇\n",
    "def simulate_pendulum_motion(t_max, delta_t):\n",
    "    theta = theta_0\n",
    "    theta_dot = theta_dot_0\n",
    "    theta_values = []\n",
    "    theta_dot_values = []\n",
    "    \n",
    "    for time in np.arange(0, t_max, delta_t):\n",
    "        theta_values.append(theta)\n",
    "        theta_dot_values.append(theta_dot)\n",
    "        \n",
    "        theta_double_dot = get_theta_double_dot(theta, theta_dot)\n",
    "        theta += theta_dot * delta_t\n",
    "        theta_dot += theta_double_dot * delta_t\n",
    "\n",
    "    return np.array(theta_values), np.array(theta_dot_values)\n",
    "\n",
    "# Directory for output frames\n",
    "output_dir = \"pendulum_frames_optimized\"\n",
    "os.makedirs(output_dir, exist_ok=True)\n",
    "\n",
    "# Simulation parameters\n",
    "t_max = 10\n",
    "delta_t_values = np.linspace(0.5, 0.01, 20)  # Reduced to 20 frames\n",
    "\n",
    "# Generate and save each frame using Matplotlib\n",
    "for i, delta_t in enumerate(delta_t_values):\n",
    "    theta_values, theta_dot_values = simulate_pendulum_motion(t_max, delta_t)\n",
    "    \n",
    "    # Plot using Matplotlib\n",
    "    plt.figure(figsize=(4, 4), dpi=80)  # Set a lower dpi for faster saving\n",
    "    plt.plot(theta_values, theta_dot_values, color='darkorange')\n",
    "    plt.title(f\"Pendulum - Time Step (delta_t): {delta_t:.4f}\")\n",
    "    plt.xlabel(\"Angle θ (radians)\")\n",
    "    plt.ylabel(\"Angular Velocity θ̇ (radians/s)\")\n",
    "    plt.xlim(-2, 2)\n",
    "    plt.ylim(-4, 4)\n",
    "    \n",
    "    # Save the frame as an image\n",
    "    frame_file = os.path.join(output_dir, f\"frame_{i:04d}.png\")\n",
    "    plt.savefig(frame_file, dpi=80)  # Lower dpi for faster saving\n",
    "    plt.close()  # Close plot to save memory\n",
    "\n",
    "print(\"Frames saved successfully.\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "work_env_trade",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.6"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
